Table 2.
Demographic and clinical overview and the comparison to the simulation success
| Baseline characteristics | Mean ± SD/number (%) | Spearman correlation | p |
|---|---|---|---|
| Age (years) | 64.1 ± 18.4 | 0.09 | 0.57 |
| BMI (kg/m2) | 25.1 ± 5.7 | 0.21 | 0.21 |
| BSA (m2) | 1.8 ± 0.2 | 0.00 | 0.99 |
| Hemoglobin (g/dl) | 9.2 ± 2.1 | 0.07 | 0.68 |
| Leukocytes (G/l) | 11.6 ± 5.4 | 0.18 | 0.27 |
| Thrombocytes (G/l) | 297.4 ± 187.8 | 0.27 | 0.11 |
| CRP (mg/dl) | 5.3 ± 5.6 | 0.05 | 0.78 |
| Creatinine (mg/dl) | 1.3 ± 1.5 | 0.14 | 0.41 |
| TSH (mU/l) | 2.4 ± 2.2 | 0.24 | 0.14 |
| Male gender | 24 (60 %) | n/a | 0.42 |
| Coronary artery disease | 6 (15 %) | n/a | 0.43 |
| Myocardial infarction | 4 (10 %) | n/a | 0.92 |
| Arterial hypertension | 22 (55 %) | n/a | 0.22 |
| Diabetes mellitus | 9 (22.5 %) | n/a | 0.54 |
| History of stroke | 8 (20 %) | n/a | 0.70 |
| Renal failure | 8 (20 %) | n/a | 0.21 |
| Smoking | 13 (32.5 %) | n/a | 0.30 |
| Alcohol | 4 (10 %) | n/a | 0.16 |
| Interventional parameters | |||
| Contrast agent (ml) | 78.4 ± 28 | − 0.02 | 0.92 |
| Dose area product (mGy·cm2) | 173.1 ± 186.2 | 0.27 | 0.11 |
| Fluoroscopic time (min.) | 25.1 ± 15.4 | 0.02 | 0.89 |
| Number of coils | 4.7 ± 4.6 | 0.49 | 0.001 * |
Baseline characteristics including patient history and clinical data as well as interventional parameters of all patients included in this study. The laboratory data corresponds to the values directly before the embolization procedure. * = statistically significant